Leukemia Clinical Trials in Austin

Showing 481-500 of 1,100 trials

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

Solid TumorClear Cell Renal Cell CarcinomaEpithelial Ovarian Cancer+6 more

23andMe, Inc.141 participantsStarted Dec 2021

Palo Alto, California, United States • Atlanta, Georgia, United States • Detroit, Michigan, United States +10 more locations

COMPLETEDPhase 174 miles

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449

This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.

MelanomaProstate CancerOvarian Cancer+6 more

Eli Lilly and Company353 participantsStarted Nov 2013

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +7 more locations

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Leukemia Trials in Other Cities

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Milademetan in Advanced/Metastatic Solid Tumors

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Other Conditions in Austin